Sanofi Ventures

Amgen Ventures has made >70 INVESTMENTS placing >$400M of the $625M Amgen has committed to support healthcare innovation and interconnectivity at all stages. Amgen Ventures offers us a unique conduit to identify and support key innovators in healthcare at early stages of translational sciences by providing investment capital and access to Amgen’s vast experience in developing leading drugs. AREAS OF INVESTMENTTHERAPEUTICS: Identify promising pipeline assets in Amgen’s therapeutic areas: oncology, immune- oncology, cardiovascular, inflammation, bone health, nephrology, metabolic disorders, and neuroscience. DRUG DISCOVERY & EMERGING TECHNOLOGIES: Improve the discovery process with new technologies including cell therapies, gene-editing and gene-therapies, regenerative medicine, and drug delivery. DIGITAL HEALTHCARE SERVICES, INFORMATION & ANALYTICS: Enhance Amgen medicines by improving real world outcomes and delivering greater value to healthcare systems, doctors, and patients.

Our unique model combines first access and proprietary rights to disruptive deal flow with an established track record of new venture formation, company building, and value creation. We invest in bold, transformative innovations to develop new drugs and technologies to improve outcomes for the market benefit of patients worldwide. Investing in early-stage venture capital We invest in seed and early-stage life science ventures, bringing Mass General Brigham’s expertise and extensive network to bear to create transformative solutions to solve unmet medical needs. Leveraging a competitive advantage Research is the driving force that advances medicine and Mass General Brigham Ventures sits at the center of the largest medical research engine in the United States. #1 in hospital medical research​ Mass General Brigham Ventures is a member of the largest hospital system-based research enterprise in the U.S., which includes Massachusetts General Hospital and Brigham and Women’s Hospital, two of the nation’s premier academic medical centers whose origins date back to the early 1800’s.​ Mass General Brigham Ventures' unique model leverages a preferred position to source technology including first access and rights to disruptive deal flow. This is an exceptional advantage that conventional venture capital funds cannot reproduce. Legacy of investing in medical innovation Mass General Brigham Ventures plays a key role in founding and funding next-generation technologies. These three transformational companies are examples of start-ups that are poised to address significant unmet medical needs. All were seeded by Mass General Brigham Ventures with founding intellectual property from Mass General Brigham. Editas Medicine: IPO Feb. 2016 (NASDAQ: EDIT) Unlocking the power and potential of CRISPR genome editing technology. CoStim Pharmaceuticals: Acquired by Novartis, Feb. 2014 Next-generation immuno-oncology drugs based on T-cell costimulatory targets. Keros Therapeutics: IPO April 2020 (NASDAQ: KROS) Novel treatments for patients suffering from hematologic and musculoskeletal disorders. Our investment strategy We invest in next-generation life science companies based on intellectual property created within our own research community. We seek strong co-investor syndicates to develop products across a range of categories including drugs, devices, diagnostics, and digital health.​ Initial investments are directed at the seed and Series A stages, where our participation attracts capital and talent into the most difficult-to-fund phase of company development. When we invest, we expect to support each portfolio company through its entire financing lifecycle. In addition to providing the necessary venture capital, we leverage our experience in starting and growing companies, our expertise in the medical industry, and our network of scientific and business talent to build great companies. Leveraging a proven approach:The annual output of high-impact invention and discovery represents a unique opportunity to create, finance, and monetize new life science-based companies. We deploy start-up capital to capture the collective expertise of our unrivaled base of scientific talent and clinical resources to bring cutting-edge science to patients Competitive advantage of Mass General Brigham: The power of collective impact from our vast research enterprise provides an unrivaled competitive advantage to build next generation life science companies capable of bringing innovative therapeutics to patients in need and delivering outstanding returns to our investors. Academic medical centers: We source deals from our five research and teaching hospitals, which collectively represent the largest teaching affiliate of Harvard Medical School.

Mirae Asset Capital Life Science was formed in 2023 as a joint venture between Mirae Asset Capital and Mirae Asset Global Investments. It is the first and only U.S. affiliate for Mirae Asset dedicated to investment in Life Science. Near-Term ValueThe majority of our investments will be Series A/B and entering the clinic within a few years to generate real value with clinical proof of concept We believe companies at this stage maximize returns given the risk; we remain open to seed opportunities where there is a clear path to value and Series C opportunities if the valuation and resulting equity ownership support meaningful returns to our investors We aim to find the right mix between first-in-class and best-in-class assets with meaningful market share and evaluate both platform and single asset approaches Calculated RiskWe are modality agnostic when it comes to therapeutics and incredibly opportunistic with diagnostics Our interest in digital health involves using AI/ML tools (e.g. quantum computing, generative biology/chemistry) for drug discovery or protein engineering We co-invest with top-tier life science investors who we know and have worked with before and leverage our operational experience to find strong management teams with excellent track records relevant to the company they are building We aim to be active investors by securing board roles whenever possible; this is a role that is familiar to us and helps mitigate risk to our investors by helping to shape the course of our investments Innovative yet Validated ModalitiesWe have selected five core therapeutic sectors to focus our investments: Oncology, Immunology, CV/Metabolic, CNS/Ophthalmology, and Rare/Genetic Disease For each of the above sectors we have defined various focus areas defined by a unique combination of validation, unmet need, market potential, and acquisition/public market interest We seek to limit biological and technical risk and prioritize small molecule, antibody approaches (includes mAbs, bsAbs/TCEs, ADCs, radiotherapeutics), and nucleic acid therapeutics (siRNA, ASOs) across these sectors Rigorous EvaluationWe leverage the combined scientific background of our team and our affiliates in Asia (medicinal chemistry, pharmacology, structural biology) to perform rigorous evaluation of each investment We prepare a comprehensive diligence memo for each investment that includes a thorough evaluation of the science, pipeline, finance, management, board, investors, operations, regulatory, IP, clinical development, and potential return to our investors We conduct calls with relevant Key Opinion Leaders for every opportunity to ensure we have the most informed and updated views from the leading voices in the field

The Boehringer Ingelheim Venture Fund Mission is to invest in the development of pioneering science – from idea to proof of concept – which offer the potential to provide significant benefits firstly for patients and also for our business. Our Investment PhilosophyActivating success: Our primary aim is to activate success for those companies and entrepreneurs we support and to earn a reputation as a long-term trusted partner. Added-value expertise: Beyond capital investment, we intend to take an active role with our portfolio companies – delivering significant added value through our own extensive drug discovery, scientific and managerial expertise and access to selected relevant experts and knowledge. Nevertheless, we also attach significant importance to confidentiality, establishing ethical walls to protect our portfolio companies and entrepreneurs. Ongoing investment: The Boehringer Ingelheim Venture Fund has an initial commitment of €300 million. Opening investments of up to €3 million per venture will be made at the early stage with subsequent staged investments made to align with each venture’s progress, up to a total of €15 million per venture (up to €7.5 million for Digital Health) over its life. Opportunities for the future: Boehringer Ingelheim would welcome the opportunity to enter into strategic partnerships with those companies in which the Venture Fund has invested. However we will be equally proud to see portfolio companies develop in their own right or enter strategic partnerships with other pharmaceutical partners. Ultimately, our goal is to add value to those companies we invest in, delivering success for them and generating revenues to finance further new investment to benefit patients. Our Investment Focus Therapeutic and Digital Health Focus Our sole focus is to search for significant enhancements in patient care through innovative and pioneering science including (but not limited to): Immunomodulation, esp. Immuno-Oncology Tissue Regeneration, e.g. stem cells, NCEs, biologics New Therapeutic Modalities, e.g. genetherapy, cell-based therapeutics Microbiome, esp. approaches based on NCEs and biologics Antiinfectives with new mechanism of action Patients Care Management, e.g. diagnosis and monitoring of disease, prevention of onset and progression of disease (incl. digital biomarkers), population management Medication adherence Digital companion therapy Digital therapy as stand alone These reflect our interest in platform technologies and the extention of the current therapeutic area focus of Boehringer Ingelheim and demonstrate our commitment to investigate new treatment modalities and technologies, beyond our existing landscape, for the potential future benefit of patients. Geographical Focus We recognise that innovation is not restricted by geography and welcome applications from entrepreneurs worldwide.

Claris Ventures SGR is a venture capital firm based in Italy, founded in 2019. Its first fund under management, Claris Biotech I, is focused on early stage investments in high potential biopharma companies arisen from the Italian R&D ecosystem – both local and international We identify and support innovation in the pharmaceutical space, investing in new companies with transformational drugs under development. We aim at the highest impact possible on highly unmet patients need, building value around strong science. Our pursuit for high potential projects involves every research center, clinical structure and company in the Italian life sciences network, whether the founding team is based in Italy or it includes Italian scientists abroad who have strong links with Italy. Claris Ventures is authorized by Banca d’Italia (Albo SGR – Sezione Gestori di FIA – n. 176) and it is a member of the AIFI (Italian Private Equity and Venture Capital Association). Strategy Claris Ventures is the first VC firm in Italy with focus on biopharma projects ready to start clinical studies in 12-24 months. Our team provides resources, capabilities and connections to complete preclinical studies and run first in human trials. We are particularly interested in oncology, immunology, rare diseases and other therapeutic areas with limited treatment opportunities. Claris Ventures allows scientific founders to focus on science and development, while supporting project management, finance and strategic development.

We invest in early-stage opportunities that complement Takeda’s pipeline and products. Our mission is to create strategic growth opportunities for Takeda by investing and nurturing Innovative Life Science Companies in areas aligned with Takeda’s R&D focuses which include; Oncology, Gastroenterology, Neuroscience, and Rare Disease. Our aim is to access and support therapeutic and platform innovation working closely with academic innovators, entrepreneurs and investors. We invest in seeds or syndicated venture investing providing to the companies access to the resources of a multinational pharmaceutical company.